Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 11:2019:8427042.
doi: 10.1155/2019/8427042. eCollection 2019.

Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery

Nagasundaram Nagarajan  1 , Edward K Y Yapp  2 , Nguyen Quoc Khanh Le  1 , Balu Kamaraj  3 , Abeer Mohammed Al-Subaie  4 , Hui-Yuan Yeh  1
Affiliations
Review

Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery

Nagasundaram Nagarajan et al. Biomed Res Int. .

Abstract

Artificial intelligence (AI) proves to have enormous potential in many areas of healthcare including research and chemical discoveries. Using large amounts of aggregated data, the AI can discover and learn further transforming these data into "usable" knowledge. Being well aware of this, the world's leading pharmaceutical companies have already begun to use artificial intelligence to improve their research regarding new drugs. The goal is to exploit modern computational biology and machine learning systems to predict the molecular behaviour and the likelihood of getting a useful drug, thus saving time and money on unnecessary tests. Clinical studies, electronic medical records, high-resolution medical images, and genomic profiles can be used as resources to aid drug development. Pharmaceutical and medical researchers have extensive data sets that can be analyzed by strong AI systems. This review focused on how computational biology and artificial intelligence technologies can be implemented by integrating the knowledge of cancer drugs, drug resistance, next-generation sequencing, genetic variants, and structural biology in the cancer precision drug discovery.

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflicts of interest.

Figures

Figure 1
Figure 1
Computational pipeline to analyze the variants and to identify the precision drugs.
Figure 2
Figure 2
Suggested pipeline for cancer precision drug discovery.
See this image and copyright information in PMC

References

    1. Massard C., Michiels S., Ferté C., et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discovery. 2017;7(6):586–595. doi: 10.1158/2159-8290.cd-16-1396. - DOI - PubMed
    1. Meric-Bernstam F., Mills G. B. Overcoming implementation challenges of personalized cancer therapy. Nature Reviews Clinical Oncology. 2012;9(9):542–548. doi: 10.1038/nrclinonc.2012.127. - DOI - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Jemal M. M., Ludwig J., Xia D., Szakacs G. Defeating drug resistance in cancer. Discovery Medicine. 2006;69:18–23. - PubMed
    1. Gottesman M. M. Mechanisms of cancer drug resistance. Annual Review of Medicine. 2002;53(1):615–627. doi: 10.1146/annurev.med.53.082901.103929. - DOI - PubMed

LinkOut - more resources